Previous 10 | Next 10 |
home / stock / cmndf / cmndf news
SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial Results demonstrated that combining SciSparc's CannAmide™ with Clearmind's MEAI has the potential to reduce alcohol consumption PR Newswire TEL AVIV, Israel , March 17, 2022 ...
Two pre-clinical trials based on MEAI exhibited a significant suppressive effect on alcohol consumption in mice TORONTO, March 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "Company") today an...
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals PR Newswire TEL AVIV, Israel , March 8, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the developm...
The companies have begun the Collaboration with a joint pre-clinical study and are expecting its results potentially to deepen the Collaboration between the parties. TORONTO, March 08, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“ C...
Vancouver, BC--(Newsfile Corp. - February 28, 2022) - Clearmind Medicine Inc. (CSE:CMND) today announced that Dr. Adi Zuloff-Shani, CEO will be attending the Q1 Virtual Investor Summit. Clearmind's CEO will present highlights of the Company, including its plans for clinical stage trials wi...
Market analyst Marissa Wright discusses the psychedelics market with a focus on psychedelic treatments for alcohol use disorder TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( CSE: CMND, FSE: CWY0 , OTC Pink: CMNDF ) (“ Clearmind &...
TORONTO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( CSE: CMND, FSE: CWY0 , OTCMKTS: CMNDF ) (“ Clearmind ” or the " Company "), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived the...
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( CSE: CMND, FSE: CWY0 , OTCMKTS: CMNDF ) (“ Clearmind ” or the " Company "), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived the...
Clearmind Medicine (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) a psychedelic drug company, has announced the speaker for the third webinar in its Psychedelics for Alcoholism series. The company has invited addiction specialist and world-renowned author Dr. Gabor Maté to talk o...
Picture1 TORONTO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( CSE: CMND, FSE: CWY0 , OTCMKTS: CMNDF ) (“ Clearmind ” or the " Company "), a psychedelic medicine biotech company focused on the discovery and development of novel psychedeli...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated h...
The first episode, "Psychedelic Novelty - Before it was Cool," introduces the company's proprietary molecule MEAI VANCOUVER, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“ Clearmind ” or the " company ...
VANCOUVER, Sept. 25, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“ Clearmind ” or the " Company "), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertr...